NASDAQ$OLMA

Olema Pharmaceuticals Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Headline financials

EPS (adj)

-$0.54

Previous: -$0.50-8.0%
Capital Expenditures

$699K

Previous: $51K+1270.6%
Free Cash Flow

-$19.3M

Previous: -$9.06M-113.0%
Net Income

-$21.6M

Previous: -$10.1M-113.6%
Operating Income

-$21.8M

Previous: -$10.1M-114.8%
Cash & Equivalents

$13.8M

Previous: $339M-95.9%
Total Assets

$296M

Previous: $343M-13.6%
Stock-Based Comp

$4.63M

Previous: $2.37M+95.1%

Revenue & EPS history

Olema · Revenue · Quarterly

$0

Q3 2025

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-0.1%

Avg return

Earnings day

-2.4%

Avg return

5 days after

+7.5%

Avg return

30 days after

52%

12 / 23 earnings

Positive

+17.0%

Q4 2021

Best reaction

-28.5%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-3.2%-7.7%-29.4%
Q3 2025+4.1%+0.6%+267.4%
Q2 2025+16.0%+20.6%+75.1%
Q1 2025+2.1%+9.6%-11.0%
Q4 2024-8.5%+4.3%+6.8%
Q3 2024-9.7%-27.9%-47.2%
Q1 2024-12.5%-18.0%+16.8%
Q4 2023-6.6%-11.2%-15.8%
Q3 2023-7.6%-7.4%-29.2%
Q2 2023+15.3%+14.0%+24.7%
Q1 2023+1.1%+6.1%-0.3%
Q4 2022+0.0%+0.3%-15.4%
Q3 2022-7.2%+5.6%-22.5%
Q2 2022-28.5%-29.4%-23.1%
Q1 2022-1.3%-3.1%+79.4%
Q4 2019+17.0%-2.2%-5.9%
Q4 2021+17.0%-2.2%-5.9%
Q3 2021+1.1%-1.9%-61.9%
Q3 2020+1.1%-1.9%-61.9%
Q2 2020+3.4%+1.9%+11.2%
Q2 2021+3.4%+1.9%+11.2%
Q1 2021+11.9%+14.8%+35.8%
Q4 2020-10.2%-23.2%-27.2%
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro